Combined Surgical and Immunotherapeutic Treatment of Patients with Fourth Stage Colon Cancer

Тарасов, В. А.; Филатов, М. В.; Kisliakova, Tatiana V.; S, Noskov Fridrih; Колосков, А. В.; Stavrovietski, Vladimir V.; Onikienko, S B; Kletchikov, Vladimir Z.; L’vov, I. B.; Varfolomeeva, E. Yu.; Близнюков, О. П.; Levina, Vera; Kiselevski, Michael V.

doi:10.1089/hyb.1999.18.99

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 shows the characteristics of the six trials included in the meta-analysis [16-21]. Three of the six trials reported data for 7 years follow-up, other three studies followed up for 1 year, 5 years and 7.6 years respectively.…”

Section: Resultsmentioning

confidence: 99%

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

et al. 2011

View full text Add to dashboard Cite

BackgroundTo evaluate the objective clinical outcomes of active specific immunotherapy (ASI) in advanced colorectal cancer (advanced CRC) and suspected minimal residual colorectal cancer (suspected minimal residual CRC).MethodsA search was conducted on Medline and Pub Med from January 1998 to January 2010 for original studies on ASI in colorectal cancer (CRC). All articles included in this study were assessed with the application of predetermined selection criteria and were divided into two groups: ASI in advanced CRC and ASI in suspected minimal residual CRC. For ASI in suspected minimal residual CRC, a meta-analysis was executed with results regarding the overall survival (OS) and disease-free survival (DFS). Regarding ASI in advanced colorectal cancer, a system review was performed with clinical outcomes.Results1375 colorectal carcinoma patients with minimal residual disease have been enrolled in Meta-analysis. A significantly improved OS and DFS was noted for suspected minimal residual CRC patients utilizing ASI (For OS: HR = 0.76, P = 0.007; For DFS: HR = 0.76, P = 0.03). For ASI in stage II suspected minimal residual CRC, OS approached significance when compared with control (HR = 0.71, P = 0.09); however, the difference in DFS of ASI for the stage II suspected minimal residual CRC reached statistical significance (HR = 0.66, P = 0.02). For ASI in stage III suspected minimal residual CRC compared with control, The difference in both OS and DFS achieved statistical significance (For OS: HR = 0.76, P = 0.02; For DFS: HR = 0.81, P = 0.03). 656 advanced colorectal patients have been evaluated on ASI in advanced CRC. Eleven for CRs and PRs was reported, corresponding to an overall response rate of 1.68%. No serious adverse events have been observed in 2031 patients.ConclusionsIt is unlikely that ASI will provide a standard complementary therapeutic approach for advanced CRC in the near future. However, the clinical responses to ASI in patients with suspected minimal residual CRC have been encouraging, and it has become clear that immunotherapy works best in situations of patients with suspected minimal residual CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

et al. 2011

View full text Add to dashboard Cite

show abstract

“…IL-2 was also used to improve the anti-tumor activity of other forms of immunotherapy [143][144][145][146][147][148][149][150] chemotherapy [151][152][153][154][155][156] and surgery [157][158][159][160][161][162][163].…”

Section: Discussionmentioning

confidence: 99%

Gastric Cancer Immunotherapy: An Overview

Romano¹,

Uggeri²,

Nespoli³

et al. 2013

JCT

View full text Add to dashboard Cite

Gastric adenocarcinoma is the third most common cancer and the second most common cause of death due to cancer worldwide. Surgery is still the major prognostic factor for gastric cancer. Patients who could not be resected have a poor prognosis with survival ranging from 3 to 11 months. There is evidence that surgical operations can cause a variety of immunological disturbances in man both in vivo and in vitro. The postoperative changes in the systemic immune response are proportional to the degree of surgical trauma leading to a generalized state of immunosuppression, which is implicated in the development of septic complications and provided a "fertile soil" for tumor cell metastasis. Immunotherapy may be a potentially promising alternative strategy for gastric cancer. In early clinical trials, systemic immunotherapy included both active vaccination directed against defined tumor-associated antigens expressed in gastric carcinoma cells and passive administration of IL-2 with some evidence of regression of metastatic gastric cancer. Other studies have applied immunotherapy in the adjuvant setting with equally promising results. For example, OK-432, a streptococcal preparation, demonstrated marginal improvement in survival for patients with stage III gastric cancer and a meta-analysis of centrally randomized controlled clinical trials indicated a significant survival benefit with combination OK-432 and chemotherapy compared to chemotherapy alone (p < 0.05). Additional data suggesting a biological and clinical benefit of subcutaneous, preoperative administration of low-dose IL-2 in colon cancer encouraged us to evaluate low-dose IL-2 therapy in the neoadjuvant setting for patients with gastric adenocarcinoma who undergo surgery and to evaluate its effects on systemic and tumor infiltrating lymphocyte numbers. We also sought to determine if neoadjuvant low-dose IL-2 could influence the clinical outcome for patients undergoing gastric resection for cancer. We report the biological, histological and clinical results with the full accrual of patients and a median follow-up of 51 months.

show abstract

Vaccines and Immunotherapy

Jain

Schulick

2011

Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer

View full text Add to dashboard Cite

Combined Surgical and Immunotherapeutic Treatment of Patients with Fourth Stage Colon Cancer

Cited by 5 publications

References 6 publications

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Gastric Cancer Immunotherapy: An Overview

Vaccines and Immunotherapy

Contact Info

Product

Resources

About